Tizanidine withdrawal syndrome is an infrequently reported condition caused by the abrupt cessation of tizanidine, a short-acting central α2-adrenergic receptor agonist. This case details a 38-year-old female who presented with moderate withdrawal syndrome induced by the abrupt discontinuation of high-dose tizanidine. The patient presented with autonomic and adrenergic hyperactivity, neuromuscular rebound, and neuropsychiatric disturbances. Management utilized multiple medications targeting hyperadrenergic and autonomic hyperactivity. This was followed by the reintroduction of tizanidine at a lowered baseline dose, which was then gradually reduced using a structured down-taper. The case illustrates an ambulatory detoxification protocol useful for tizanidine withdrawal management.
References
[1]
Suárez-Lledó, A., Padullés, A., Lozano, T., Cobo-Sacristán, S., Colls, M. and Jódar, R. (2018) Management of Tizanidine Withdrawal Syndrome: A Case Report. ClinicalMedicineInsights: CaseReports, 11, 1-3. https://doi.org/10.1177/1179547618758022
[2]
Morgom, M., Anjum, S., Elgassim, M.A., Awadelseed, S. and Saeed, L. (2024) Emergency Response to Tizanidine Overdose: A Case Report on Critical Care Strategies. Cureus, 16, e70696. https://doi.org/10.7759/cureus.70696
[3]
Hannum, A., Spano, I. and Ofori, E. (2026) A Review of Alpha-2 Adrenergic Agents Implicated in Opioid Use Disorder. ACSChemicalNeuroscience, 17, 899-919. https://doi.org/10.1021/acschemneuro.5c00970
[4]
Omer, M., Yigit, Y., Alkahlout, B.H., Mohamed, E.H., Khalil, S. and Azad, A.M. (2024) Maximal Tizanidine Withdrawal Managed with Dexmedetomidine: A Vital Intervention. OxfordMedicalCaseReports, 2024, omae005. https://doi.org/10.1093/omcr/omae005
[5]
Heck, D.A. and Bylund, D.B. (1997) Mechanism of Down-Regulation of Alpha-2 Adrenergic Receptor Subtypes. TheJournalofPharmacologyandExperimentalTherapeutics, 282, 1219-1227. https://doi.org/10.1016/s0022-3565(24)36916-2
[6]
Nguyen, T.N., Despande, T., Abdipour, A. and Bhullar, J. (2026) Tizanidine Withdrawal Presenting as Hypertensive Emergency with Recurrent AKI. KidneyInternationalCaseReports, 1, Article ID: 100016. https://doi.org/10.1016/j.kintcr.2026.100016
[7]
Daniels, N.F., Ridwan, R. and Vasileva, A.D. (2023) Management of Tizanidine Abuse and Withdrawal in a 53-Year-Old Woman: A Case Report. SNComprehensiveClinicalMedicine, 5, Article No. 14. https://doi.org/10.1007/s42399-022-01356-1
[8]
Tanimura, J. and Hashimoto, T. (2024) Case of Tizanidine Withdrawal Showing Hallucination, Decorticate Posture and Tremor, with Hypersympathetic Vital Signs. BMJCaseReports, 17, e254966. https://doi.org/10.1136/bcr-2023-254966
[9]
Escobar Gil, T., McGeorge, K.J. and Jones, A.J. (2024) A Case of Tizanidine Withdrawal and Road to Recovery. Cureus, 16, e53444. https://doi.org/10.7759/cureus.53444
[10]
American Psychiatric Association (2022) Other (or Unknown) Substance Use Disorder. In: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision, American Psychiatric Association.
[11]
de Graaf, E.M., Oosterveld, M., Tjabbes, T. and Stricker, B.H.C. (1996) A Case of Tizanidine-Induced Hepatic Injury. JournalofHepatology, 25, 772-773. https://doi.org/10.1016/s0168-8278(96)80252-2
[12]
Kitta, A., Wippel, A., Richwien, P., Prager, G., Adamidis, F., Masel, E.K., et al. (2020) Using Clonidine in the Treatment of Tizanidine Abuse and Withdrawal: A Case Report of a Patient with Somatoform Pain Disorder. JournalofSubstanceUse, 25, 535-537. https://doi.org/10.1080/14659891.2020.1738574
[13]
Morgom, M., Sabir, D.M., Elbashir, H., Saeed, L., Alamin, A., Abuazab, Y., et al. (2023) A Case of Tizanidine Withdrawal Syndrome: Features and Management in the Emergency Department. Cureus, 15, e49248. https://doi.org/10.7759/cureus.49248
[14]
Busto, U. and Sellers, E.M. (1986) Pharmacokinetic Determinants of Drug Abuse and Dependence: A Conceptual Perspective. ClinicalPharmacokinetics, 11, 144-153. https://doi.org/10.2165/00003088-198611020-00004
